Hosted on MSN1mon
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue EstimatesA quarter ago, it was expected that this biotechnology company would post a loss of $1.45 per share when it actually produced a loss of $1.40, delivering a surprise of 3.45%. Over the last four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results